We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Allergan plc | NYSE:AGN | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 193.02 | 0 | 01:00:00 |
From May 2019 to May 2024
By Dave Sebastian
The Food and Drug Administration said it has approved Ubrelvy, Allergan PLC's (AGN) migraine tablets.
Allergan USA Inc., an Allergan entity, tested Ubrelvy's performance on the treatment of migraine in adults in two trials involving 1,439 patients with a history of migraine, with or without visual disturbance, the agency said Monday.
The agency said the proportion of patients who had reduced headache two hours after treatment was greater in those who took Ubrelvy than those who took the placebo. There was also a larger proportion of patients whose migraine symptoms such as nausea and light sensitivity stopped two hours after treatment with Ubrelvy, FDA said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
December 23, 2019 15:18 ET (20:18 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Allergan Chart |
1 Month Allergan Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
